In this issue of Blood, Byrd and colleagues report on the outcomes of a phase 1/2 study of anti-CD23 monoclonal antibody lumiliximab combined with FCR in patients with refractory/relapsed CLL.
No takes yet. Share an insight, caveat, or question.
Tadeusz Robak (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: